Immune response to animal epithelia allergens

The immune response to animal epithelia allergens is a complex physiological process characterized by a Type I hypersensitivity reaction to proteins found in animal dander, saliva, or urine (NIH, 2023). This response is initiated when the immune system misidentifies these harmless proteins as threats, leading to the production of allergen-specific IgE antibodies by B cells. These IgE molecules bind to high-affinity receptors on mast cells and basophils; subsequent exposure to the allergen causes cross-linking of the IgE, triggering the release of potent inflammatory mediators such as histamine and leukotrienes (StatPearls, 2023). This cascade results in the clinical symptoms of allergy, including airway inflammation, mucus production, and bronchoconstriction, often manifesting as allergic rhinitis or asthma (AAAAI, 2024). While not a single molecular target, this pathway is managed by drugs that target specific mediators like IgE (e.g., omalizumab) or cytokines such as IL-4 and IL-13 (e.g., dupilumab). Additionally, allergen-specific immunotherapy (AIT) is used to induce long-term immunological tolerance by gradually exposing the patient to increasing doses of the specific animal epithelial proteins (PubMed, 2022). This therapeutic approach aims to shift the immune profile from a Th2-mediated allergic response to a more tolerant Th1 or regulatory T cell (Treg) mediated state.

Other names

Animal dander allergyAnimal epithelia allergyHypersensitivity to animal allergensPet allergyAllergic response to animal dander

Pharmacological management involves the neutralization of circulating IgE to prevent mast cell degranulation, the blockade of Th2-type cytokine signaling (IL-4, IL-5, IL-13) or TSLP to reduce eosinophilic inflammation, the antagonism of histamine H1 receptors or leukotriene receptors to alleviate acute symptoms, and the induction of immunological tolerance through allergen-specific immunotherapy.